IL17A and candidiasis: For IL17 neutralization, the data are clearly consistent with the known capacity of APS1/APECED patients’ antibodies to neutralize Th17-family cytokines (Kisand et al., 2010, Puel et al., 2010), thereby predisposing to Candida infection.